PV Bulletin

Introduction of Mandatory Annual Safety Report (ASR) Module in CTIS

The EMA announces a new ASR module in the Clinical Trials Information System (CTIS), becoming the mandatory channel for ASR submissions for clinical trials under Regulation (EU) No 536/2014.

Primary source: Download medicine data | European Medicines Agency (EMA)

PV Impact Brief

Urgency: HighConfidence: high

What changed

The ASR module in the CTIS becomes mandatory for submitting Annual Safety Reports for clinical trials, requiring compliance with new submission protocols established under Regulation (EU) No 536/2014.

Why it matters

This change impacts clinical trial sponsors as they are required to adapt their safety reporting workflows to ensure compliance with the new mandatory channel for ASR submissions.

Action needed

Clinical trial sponsors must update internal standard operating procedures (SOPs), conduct staff training on the functionality of the new ASR module, and utilize the CTIS training environment to ensure readiness for compliance with the new workflow.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
ICSRCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Notice
Policy status
new
Publication date
12 June 2026
Policy change
Announcement and technical overview of a new Annual Safety Report (ASR) module within the Clinical Trials Information System (CTIS). This module will become the mandatory channel for submitting and managing ASRs (equivalent to Development Safety Update Reports/DSURs) for clinical trials conducted under the Clinical Trials Regulation (Regulation (EU) No 536/2014).

Key changes

Introduction of a dedicated ASR safety module in CTIS; transition to a mandatory submission channel for ASRs; updated functionalities for managing safety reporting in the system; new process for accessing the CTIS training environment.

Affected workflows

ICSRCountry Compliance

Responsible groups

SponsorsPV OperationsClinical SafetyRegulatory Affairs

PV impact

Clinical trial sponsors must prepare for the mandatory transition to the CTIS ASR module for safety report submissions. PV operations and clinical safety teams will need to update internal SOPs, train staff on the new module's functionalities, and use the CTIS training environment to ensure compliance with the new submission workflow.

View regulator source

Source document details

Evidence and confidence

Confidence: highSource updated: Jun 12, 2026

Full briefing

Practical implication

Clinical trial sponsors must update internal standard operating procedures (SOPs), conduct staff training on the functionality of the new ASR module, and utilize the CTIS training environment to ensure readiness for compliance with the new workflow.

The new ASR module will be the required method for submitting and managing Annual Safety Reports, analogous to Development Safety Update Reports (DSURs). This transition necessitates that clinical trial sponsors prepare by updating internal procedures and training staff on the new system functionalities.

What changed: The ASR module in the CTIS becomes mandatory for submitting Annual Safety Reports for clinical trials, requiring compliance with new submission protocols established under Regulation (EU) No 536/2014.

Why it matters: This change impacts clinical trial sponsors as they are required to adapt their safety reporting workflows to ensure compliance with the new mandatory channel for ASR submissions.

Practical implication: Clinical trial sponsors must update internal standard operating procedures (SOPs), conduct staff training on the functionality of the new ASR module, and utilize the CTIS training environment to ensure readiness for compliance with the new workflow.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward